Skip to main content

LEO Pharma appoints new Executive Vice President of Global Product Supply

Written by: Editor
Published on: 3 Aug 2022

Appointment [square]Ballerup, Denmark, August 03, 2022 – LEO Pharma A/S announced today the appointment of Sven Hauptmann as its new Executive Vice President of Global Product Supply, effective August 1, 2022.

Sven joins LEO Pharma with more than 25 years of international experience from Roche where he has held numerous leadership positions within supply chain and manufacturing. He comes with a strong track record delivering world-class results e.g., as Site Lead for Roche’s production site in Ireland, Vice President for Small Molecules Manufacturing and most recently as Senior Vice President for Global Drug Product Manufacturing.

Sven holds a Ph.D. in Chemistry from the Technical University in Darmstadt, Germany and an Executive MBA from Northwestern University – Kellogg School of Management.

“I am delighted and proud to welcome Sven to LEO Pharma. I strongly believe he will bring significant value to our business and drive the transformation agenda in our global product supply as we progress on our ambitious strategy toward 2025,” said Christophe Bourdon, President and CEO of LEO Pharma.

“I am thrilled to join LEO Pharma at such exciting times. LEO Pharma has a long and proud history of innovation and I feel strongly about our mission to advance the standard of care for the benefit of people with skin conditions, their families and society,” said Sven Hauptmann.

Sven Hauptmann succeeds Rhonda Duffy who will be leaving LEO Pharma after more than 29 years with the company. It has been Rhonda’s desire to take time off and spend more time with her family. Rhonda has kindly agreed to ensure a smooth handover in the coming months.

“I would like to thank Rhonda Duffy for her loyalty to LEO Pharma, her drive for constant improvements, and her impressive efforts to bring safe and innovative products to patients. Rhonda’s many years with the company is a testament to her passion for making a difference to patients,” said Christophe Bourdon, President and CEO of LEO Pharma.